Abstract
Endostatin is a potent anti-angiogenic and anti-tumor protein capable of regressing tumors without inducing acquired resistance. Since it is a fragment of the parental molecule, collagen XVIII, its endogenous production depends on the activity of a specific proteolytic enzyme. While such an enzyme has been described in mice, a human counterpart has not been identified so far. Here, we searched for this enzyme by using a fluorescence resonance energy transfer peptide containing the cleavage site of human collagen XVIII. We found that the cleavage activity was present in various murine and human tumor cells but not in untransformed cells. It was ascribed to a large protein complex identified as an extracellular form of proteasome 20S. Since circulating proteasome 20S has recently emerged as an important marker of tumor progression, the possibility of proteasomes controlling the production of angiostatic endostatin may inspire the development of new anticancer therapies.
Similar content being viewed by others
References
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285
Boehm T, Folkman J, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407
Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR (1994) Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 91:4229–4233
Rehn M, Pihlajaniemi T (1994) Alpha 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct distribution, and homology with type XV collagen. Proc Natl Acad Sci USA 91:4234–4238
Seppinen L, Pihlajaniemi T (2011) The multiple functions of collagen XVIII in development and disease. Matrix Biol 30:83–92
Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T (1998) The short and long forms of type XVIII collagen show clear tissue specificities in their expressions and location in basement membrane zones in humans. Am J Pathol 153:611–626
Schuppan D, Cramer T, Bauer M, Strefeld T, Hahn EG, Herbst H (1998) Hepatocytes as a source of collagen type XVIII endostatin. Lancet 352:879–880
Suzuki OT, Sertié AL, Der Kaloustian VM, Kok F, Carpenter M, Murray J, Czeizel AE, Kliemann SE, Rosemberg S, Monteiro M, Olsen BR, Passos-Bueno MR (2002) Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome. Am J Hum Genet 71:1320–1329
Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J (1999) The generation of endostatin is mediated by elastase. Cancer Res 59:6052–6056
Felbor U, Dreier L, Bryant RA, Plogh HL, Olsen BR, Mothes W (2000) Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19:1187–1194
Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486:247–251
Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkilä P, Rehn M, Sorsa T, Salo T, Pihlajaniemi T (2005) Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 307:292–304
Veillard F, Saidi A, Burden RE, Scott CJ, Gillet L, Lecaille F, Lalmanach G (2011) Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem 286:37158–37167
Bohem T, O’Reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252:190–194
Sjin RMTT, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K (2005) A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65:3656–3663
Ding YH, Javaherian K, Lo KM, Chopra R, Boehm T, Lanciotti J, Harris BA, Li H, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley DC (1998) Zinc-dependent dimers observed in crystals of human. Proc Natl Acad Sci USA 95:10443–10448
Fu Y, Luo Y (2010) The N-terminal integrity is critical for the stability and biological functions of endostatin. Biochemistry 49:6420–6429
Ständker L, Schrader M, Kanse SM, Jürgens M, Forssmann WG, Preissner KT (1997) Isolation and characterization of the circulating form of human endostatin. FEBS Lett 420:129–133
Hasle H, Clemmensen IH, Mikkelsen M (2000) Incidence of cancer in individuals with Down syndrome. Tidsskr Norske Laege 120:2878–2881
Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR (2001) High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumors. Eur J Hum Genet 9:811–814
Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertié AL, Zorick T, Soares F, Camargo A, Moreira ES, di Loreto C, Moreira-Filho CA, Simpson A, Oliva G, Passos-Bueno (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:7375–7378
Chen J, Hamm LL, Kleinpeter MA, Husserl F, Khan IE, Chen CS, Liu Y, Mills KT, He C, Rifai N, Simon EE, He J (2012) Elevated plasma levels of endostatin are associated with chronic kidney disease. Am J Nephrol 35:335–340
Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK (2002) Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95:1637–1643
Hsieh MY, Lin ZY, Chuang WL (2011) Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Kaohsiung J Med Sci 27:314–322
Hu MM, Hu Y, Zhang HQ, Jia WY, Qian Z, Yang Y, Li BL (2014) Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer. Biomed Rep 2:898–904
Susuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, Sekine Y, Yoshida S, Hiroshima K, Fujisawa T (2002) Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 35:29–34
Hirata IY, Cezari MHS, Nakaie CR, Boschcov P, Ito AS, Juliano MA, Juliano L (1994) Internally quenched fluorogenic protease substrates: solid-phase synthesis and fluorescence spectroscopy of peptides containing ortho-aminobenzoyl/dinitrophenyl groups as donor-acceptor pairs. Lett Peptide Sci 1:299–308
Von Krüger WM, Lery LM, Soares MR, de Neves-Manta FS, Batista e Silva CM, Neves-Ferreira AG, Perales J, Bisch PM (2006) The phosphate-starvation response in Vibrio cholerae O1 and phoB mutant under proteomic analysis: disclosing functions involved in adaptation, survival and virulence. Proteomics 6:1495–1511
Lee MC, Alpaugh ML, Nguyen M, Deato M, Dishakjian L, Barsky SH (2000) Myoepithelial-specific CD44 shedding is mediated by a putative chymotrypsin-like sheddase. Biochem Biophys Res Commun 279:116–123
Navom A, Ciechanover A (2009) The 26 S proteasome: from basic mechanism to drug targeting. J Biol Chem 284:33713–33718
Vaithilingam IS, McDonald W, Malott DW, Del Maestro RF (1995) An extracellular proteasome-like structure from C6 astrocytoma cells with serine collagenase IV activity and metallo-dependent activity on alpha-casein and beta-insulin. J Biol Chem 270:4588–4593
Rivett AJ, Palmer A, Knecht E (1992) Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in culture cells. J Histochem Cytochem 40:1165–1172
Sixt SU, Dahlmann B (2008) Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta 1782:817–823
Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP, Meunier L (2005) High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 152:948–953
Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF, Bureau JP (2001) Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 15:2493–2500
Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, Bureau JP, Ouali A (2002) Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods 1:183–193
Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A (1993) Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 121:215–223
Sixt SU, Beiderlinden M, Jennissen HP, Peters J (2007) Extracellular proteasome in the human alveolar space: a new housekeeping enzyme? Am J Physiol Lung Cell Mol Physiol 292:1280–1288
Egerer K, Kuckelkorn U, Rudolph PE, Rückert JC, Döner T, Burmester GR, Kloetzel PM, Feist E (2002) Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29:2045–2052
Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G, Ankersmit HJ (2005) Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Investig 35:399–403
Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E, de Graft-Johnson JE, Zalewska A, Luczynska M, Novak D (2006) Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis—association with pulmonary involvement. Clin Exp Rheumatol 24:508–513
Sumi M, Satoh H, Kagohashi K, Ishikawa H, Sekizawa K (2005) Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis. J Clin Lab Anal 19:146–149
Bochmann I, Ebstein F, Lehmann A, Wohlschlaeger J, Sixt SU, Kloetzel PM, Dahlmann B (2014) T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes. J Cell Mol Med 18:59–68
Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, Choo A, Lim SK (2012) Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteom 2012:971907
Zhu Y, Chen X, Pan Q, Wang Y, Su S, Jiang C, Li Y, Xu N, Wu L, Lou X, Liu S (2015) A comprehensive proteomics analysis reveals a secretory path- and status- dependent signature of exosomes released from tumor-associated macrophages. J Proteom Res 14:4319–4331
Vadas P, Pruzanski W, Stefanski E, Ellies LG, Aubin JE, Sos A, Melcher A (1991) Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumor necrosis factor action. Immunol Lett 28:187–193
Lin MK, Farewell V, Vadas P, Bookmann AA, Keystone EC, Pruzanski W (1996) Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 23:1162–1166
Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Lösche W, Kinscherf R, Deigner HP (2005) Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 19:1719–1721
Doehner W, Bunck AC, Rauchhaus M, von Haehling S, Brunkhorst FM, Cicoira M, Tschope C, Ponikowski P, Claus RA, Anker SD (2007) Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 28:821–828
Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Willams KJ, Tabas I (1998) Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 273:4081–4088
Morales P, Pizarro E, Kong M, Jara M (2004) Extracellular localization of proteasomes in human sperm. Mol Reprod Dev 68:115–124
Sutovsky P, Manandhar G, McCauley TC, Caamaño JN, Sutovsky M, Thompson WE (2004) Proteasomel interference prevents zona pellucida penetration and fertilization in mammals. Biol Reprod 71:1625–1637
Wojcik C, Benchaib M, Lornage J, Czyba JC, Guerin JF (2000) Proteasomes in human spermatozoa. Int J Androl 23:169–177
Acknowledgements
We thank Dr. Marilene Demasi and Dr. Claudio Masuda for helpful discussions and for the donation of reagents. This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP—Project—12/50191-4R), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq—Projects—471340/2011-1 and 470388/2010-2).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure 1
A protease isolated from human glioblastoma produces endostatin in cultures of human umbilical vein endothelial cells. A protein fraction was isolated from a primary culture of human glioblastoma exactly as done to produce F6 out of EOMA (see Materials and Methods). Such fraction (100 μl) was incubated with a confluent culture of HUVEC in a six-well plate (9.6 cm2) for 2 h at 37°C in growth medium (199 plus 20% FBS). Culture supernatant was analyzed in SDS-PAGE 12% followed by western blot using a polyclonal anti-endostatin antibody (Millipore, AB1878). A band of 20 kDa was detected, whereas such band was strongly reduced when the experiment was carried out in the presence of 10 μM AEBSF. (DOCX 95 kb)
Rights and permissions
About this article
Cite this article
Reiss-Pistilli, M.L.V., Schuppan, D., Barroso, M.M.S. et al. An extracellular proteasome releases endostatin from human collagen XVIII. Angiogenesis 20, 125–137 (2017). https://doi.org/10.1007/s10456-016-9533-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10456-016-9533-6